Roger Lee Papke, Ph.D.

papke

Contact Information

Dr. Roger Lee Papke
Department of Pharmacology and Therapeutics
University of Florida College of Medicine
Academic Research Building
1200 Newell Drive
PO Box 100267
Gainesville, Florida 32610
Office Location: Academic Research Building, R5-295
Office Phone: (352) 392-4712
Laboratory Phone: (352) 392-3257
Email: rlpapke@ufl.edu
Websites: Department of Pharmacology & Therapeutics Profile
Laboratory Website of Dr. Papke
CV

Position

Professor, Department of Pharmacology and Therapeutics, University of Florida
Affiliate Professor, Department of Neuroscience, University of Florida

Training

BA, Biology and Classical Civilization, Washington Square College of Arts and Sciences, New York University
MS, Graduate School of Arts and Sciences, New York University (Thesis Advisor: Dr. Fleur L. Strand)
PhD, Neurobiology and Behavior, Graduate School of Arts and Science, Cornell University (Thesis Advisor: Dr. Robert Oswald)
Postdoctoral Associate, Department of Pharmacology, Cornell University
Postdoctoral Fellow, Molecular Neurobiology Laboratory, Salk Institute

Research Interests

Dr. Papke studies the physiology, pharmacology, and biophysics of neurotransmitter receptors with a special emphasis on the function of nicotinic acetylcholine receptors in the brain. These are the receptors which mediate the effects of nicotine on human behavior. His research explores how these neuronal nicotinic acetylcholine receptors function as ligand-gated ion channels, identifying parts of the molecule which are involved with the binding of neurotransmitter and the conformational change associated with receptor activation. His work also seeks to characterize the selectivity of experimental nicotinic agonists for specific receptor subtypes in the brain. With this understanding, they hope to identify the mechanisms through which nicotine-like substances may alleviate some of the learning and memory impairments in animal models of dementia. The ongoing clinical development of new experimental drugs may lead to novel therapeutics for the treatment of Alzheimer’s disease.

Publications

  • Horenstein NA, Quadri M, Stokes C, Shoaib M, Papke RL. Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds. Nicotine Tob Res. 2017 Oct 3. doi: 10.1093/ntr/ntx187.
  • Horenstein NA, Papke RL. Anti-inflammatory Silent Agonists. ACS Med Chem Lett. 2017 Sep 26;8(10):989-991. doi: 10.1021/acsmedchemlett.7b00368. eCollection 2017 Oct 12.
  • Hueffer K, Khatri S, Rideout S, Harris MB, Papke RL, Stokes C, Schulte MK. Rabies virus modifies host behaviour through a snake-toxin like region of its glycoprotein that inhibits neurotransmitter receptors in the CNS. Sci Rep. 2017 Oct 9;7(1):12818. doi: 10.1038/s41598-017-12726-4.
  • Quadri M, Stokes C, Gulsevin A, Felts ACJ, Abboud KA, Papke RL, Horenstein NA. Sulfonium as a Surrogate for Ammonium: A New α7 Nicotinic Acetylcholine Receptor Partial Agonist with Desensitizing Activity. J Med Chem. 2017 Sep 28;60(18):7928-7934. doi: 10.1021/acs.jmedchem.7b00875. Epub 2017 Sep 14.
  • Abbas M, Alzarea S, Papke RL, Rahman S. The α7 nicotinic acetylcholine receptor positive allosteric modulator attenuates lipopolysaccharide-induced activation of hippocampal IκB and CD11b gene expression in mice. Drug Discov Ther. 2017;11(4):206-211. doi: 10.5582/ddt.2017.01038.
  • Jin Y, Huang X, Papke RL, Jutkiewicz EM, Showalter HD, Zhan CG. Design, synthesis, and biological activity of 5′-phenyl-1,2,5,6-tetrahydro-3,3′-bipyridine analogues as potential antagonists
    of nicotinic acetylcholine receptors. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4350-4353. doi: 10.1016/j.bmcl.2017.08.025. Epub 2017 Aug 14.

Pubmed Profile